AstraZeneca PLC
AZN 89.10 (0.72%) 0.64
Health Care
Pharmaceuticals
Quality Checklist 5/8
ROIC > 10%
Debt/Equity < 1
Net Margin > 10%
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
5Y Shares Out Change < 0%
Current Ratio > 1
Quick Ratio > 1
0.0%of Portfolio
My holdings
Day change:
Total change:
Shares:Cost basis:
Market cap: $276.21(B)
EV: $300.27(B)
Total Equity: $45.97(B)
Earnings date: Feb-10-2026
P/E: 29.39
Forward P/E: 19.32
P/FCF: 21.83
P/S: 4.75
P/B: 6.02
EPS: $3.0
EPS (fwd): $4.6
FCF/share: $4.1
Revenue/share: $18.8
Book value/share: $14.8
ROIC: 12.5%
ROA: 8.6%
ROE: 21.7%
Debt/Equity: 0.71
Current Ratio: 0.90
Gross margin: 83.3%
Operating margin: 22.0%
Net margin: 16.2%
Dividend/share: $1.6
Div. yield: 1.76%
AZN Valuation & Price Targets
Current Price
$89.1
Favorite Valuation Methods
More Valuation Methods
DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A
PEvaluation
46% overvalued
Low
$36.1
Mid
$48.1
High
$60.1
Current price
$89.1
Fair P/E
Margin of safety
EPS
Market Model
Economic moat: None/narrow
EPS Estimates
| Low | Avg | High | # | |
| FY+1 | 4.5 | 4.6 | 4.7 | 18 |
| FY+2 | 5.0 | 5.2 | 5.7 | 18 |
| FY+3 | 5.3 | 5.9 | 6.5 | 17 |
| FY+4 | 5.5 | 6.4 | 7.2 | 9 |
| FY+5 | 5.6 | 7.2 | 8.2 | 8 |
Analyst Price Targets
N/A
No analyst price targets
No analyst price targets
Analyst Recommendations
2-stage DCF
First Stage Duration: 5 Years | |
| Starting Free Cash Flow | |
First Stage Growth Rate | |
LowMidHigh | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Discounted Cash Flow
Forecast years: 5 Years | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Discounted Cash Flow (exit mult.)
Forecast years: 5 Years | |
Exit FCF Multiple | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Dividend Discount Model
| Annual Dividend | |
First Stage Length (Years): 0 Years | |
| First Stage Growth Rate | |
| Final Growth Rate | |
| Discount Rate | |
EPS Growth
Forecast years: 5 Years | |
| Starting EPS | |
EPS Growth Rate | |
LowMidHigh | |
Final P/E | |
LowMidHigh | |
| Discount Rate | |
Revenue Growth Valuation
Forecast Years: 10 Years | |
| Base Revenue | |
Revenue Growth Rate | |
LowMidHigh | |
Final Net Margin | |
LowMidHigh | |
Final P/E Ratio | |
LowMidHigh | |
| Discount Rate | |
Peter Lynch Fair Value
| Earnings Per Share | |
| Growth Rate |
Graham Formula
| Earnings Per Share | |
| EPS Growth (7-10 years) | |
| Government Bond Rate |